Monthly Archives: November 2009
XOMA’s NASDAQ delisting saga continues
The on-off saga of XOMA’s delisting continues with news that XOMA has received a letter from NASDAQ indicating that the exchange has concluded that XOMA’s previously-announced common share financing completed on September 30, 2009 did not comply with NASDAQ’s Listing … Continue reading
Filed under Uncategorized
Sanofi-aventis and Intelliject partner for anaphylaxis injector
On November 30 3009 Sanofi-aventis signed an exclusive licensing agreement with Intelliject Inc for a novel epinephrine injector for the emergency treatment of anaphylaxis in North America (US and Canada). Sanofi-aventis is to take responsibility for manufacturing and commercial activities … Continue reading
Filed under alliances
Partnering Profile: Sanofi-aventis
How many partners does Sanofi-aventis have? Like many pharmaceutical companies Sanofi-aventis does not reveal its exact number of alliances, but in 2008 the company’s Anuual Report indicated the company was stepping up the number of alliances it would like to … Continue reading
Filed under alliances
Partnering Profile: Eli Lilly
How many partners does Eli Lilly have? Like many pharmaceutical companies Eli Lilly does not provide the exact number of collaborations it has. Some idea of how strong alliances are within the company can be seen from its product pipeline … Continue reading
Filed under alliances
Resarch collaboration between Oxford Expression Technologies, Paratechs and LifeSensors
On November 27 2009 Oxford Expression Technologies Ltd signed research collaboration agreements with ParaTechs and LifeSensors to enhance and expand OET’s flashBAC™ portfolio of baculovirus protein expression systems. The collaboration with ParaTechs will investigate the potential impact of expressing a … Continue reading
Filed under alliances
Pfizer acquires stem cell therapy assets from Axordia
On November 23 2009 Pfizer Ltd acquired for US$0.75 million certain assets related to stem cell therapies from Axordia Limited, a whole-owned subsidiary of Intercytex Group plc, and a developer of stem cell therapies for human diseases.
Filed under acquisitions
Biovitrum sells Cambridge Biotechnology Ltd to Proximagen Neuroscience
On November 24 2009 Biovitrum AB completed the sale of its wholly-owned subsidiary Cambridge Biotechnology Ltd and certain drug development programmes to Proximagen Neuroscience plc. The drug development programmes consist of the pre-clinical stage programmes VAP-1 and Trk A as … Continue reading
Filed under acquisitions
Merck & Co extend partnership with Idera
On November 25 2009 Merck & Co and Idera announced they are extending their three year partnership for fourth year. Begun in December 2006 the collaboration aims to develop vaccines that could be used against cancer, infectious diseases, and Alzheimer’s … Continue reading
Filed under alliances
Novartis and Idera to end researach collaboration for asthma and allergy treatments
As of Februrary 2010 Novartis is to terminate its research collaboration agreement begun with Idera Pharmaceuticals Inc in May 2005. The aim of the collaboration was to discover, develop, and commercialize TLR9 agonists that are based on Idera’s proprietary IMO … Continue reading
Filed under alliances
Merck & Co launches phase II trial for Karo Bio’s drug
On November 26 2009 Merck & Co Inc indicated that it plans to start a clinical phase IIa trial with the biotechnology company Karo Bio’s lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. The randomized, … Continue reading
Filed under alliances
